

## **Are cholesterol-lowering statins as good as we think?**

**Paula Byrne for Evidently Cochrane 15 December 2022**

### **References**

Albarqouni L, Doust J, Glasziou P. Patient preferences for cardiovascular preventive medication: a systematic review. *Heart* 2017 Oct;103(20):1578-1586. doi: 10.1136/heartjnl-2017-311244. Available from: [https://core.ac.uk/reader/196605102?utm\\_source=linkout](https://core.ac.uk/reader/196605102?utm_source=linkout)

Byrne P, Demasi M, Jones M, Smith SM, O'Brien KK, DuBroff R. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. *JAMA Intern Med* 2022 May 1;182(5):474-481. doi: 10.1001/jamainternmed.2022.0134. Erratum in: *JAMA Intern Med* 2022 May 1;182(5):579. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2790055>

Geddes L. 'Nocebo effect' cause of most statin side-effects, study suggests. *Guardian News*, 15 November 2020. Web. 09 December 2022. <https://www.theguardian.com/society/2020/nov/15/nocebo-effect-cause-of-most-statin-side-effects-research-suggests>

Organisation for Economic Cooperation and Development (OECD). Chapter 9 Pharmaceutical sector: Pharmaceutical consumption. In: *Health at a glance 2021: OECD Indicators*. Paris: OECD; November 2021. Available from: [https://www.oecd-ilibrary.org/sites/ae3016b9-en/1/3/9/3/index.html?itemId=/content/publication/ae3016b9-en&csp\\_ca413da5d44587bc56446341952c275e&itemIGO=oecd&itemContentType=book#figure-d1e13925](https://www.oecd-ilibrary.org/sites/ae3016b9-en/1/3/9/3/index.html?itemId=/content/publication/ae3016b9-en&csp_ca413da5d44587bc56446341952c275e&itemIGO=oecd&itemContentType=book#figure-d1e13925)